$LXRX
LEXICON PHARMACEUTICALS, INC.

2014 Q1 Form 10-K Financial Statement

#000106282214000009 Filed on March 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2012 Q4 2012 Q3
Revenue $277.0K $218.0K $372.0K
YoY Change -23.06% -36.44% 4.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.300M $3.900M $4.400M
YoY Change 23.26% -2.5% 7.32%
% of Gross Profit
Research & Development $23.95M $21.00M $19.19M
YoY Change 17.84% -25.27% -2.36%
% of Gross Profit
Depreciation & Amortization $644.0K $900.0K $1.100M
YoY Change -18.79% -18.18% -8.33%
% of Gross Profit
Operating Expenses $30.75M $24.70M $29.43M
YoY Change 18.65% -26.71% 13.0%
Operating Profit -$30.47M -$24.49M -$29.06M
YoY Change 19.24% -26.54% 13.11%
Interest Expense $457.0K -$500.0K $527.0K
YoY Change -9.68% 0.0% -5.89%
% of Operating Profit
Other Income/Expense, Net $94.00K $100.0K $4.000K
YoY Change 176.47% -95.45%
Pretax Income -$30.80M -$24.90M -$29.50M
YoY Change 18.46% -26.33% 13.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$30.84M -$24.87M -$29.54M
YoY Change 18.71% -26.51% 13.16%
Net Earnings / Revenue -11131.77% -11409.63% -7940.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$419.6K -$343.4K -$421.4K
COMMON SHARES
Basic Shares Outstanding 513.8M shares 512.4M shares 494.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.90M $222.8M $206.4M
YoY Change -50.23% -20.8% 43.63%
Cash & Equivalents $46.52M $30.42M $20.76M
Short-Term Investments $51.40M $192.4M $185.7M
Other Short-Term Assets $6.570M $6.349M $9.004M
YoY Change -22.14% 69.4% 107.61%
Inventory
Prepaid Expenses
Receivables $471.0K $1.378M $233.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $105.4M $230.9M $216.1M
YoY Change -48.95% -19.19% 45.04%
LONG-TERM ASSETS
Property, Plant & Equipment $39.96M $42.63M $43.52M
YoY Change -6.25% -8.15% -8.09%
Goodwill $44.54M $44.54M $44.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles $53.56M $53.56M $53.56M
YoY Change 0.0% 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $133.0K $109.0K $135.0K
YoY Change 51.14% -46.83% -51.96%
Total Long-Term Assets $138.2M $140.8M $141.8M
YoY Change -1.86% -2.68% -2.73%
TOTAL ASSETS
Total Short-Term Assets $105.4M $230.9M $216.1M
Total Long-Term Assets $138.2M $140.8M $141.8M
Total Assets $243.6M $371.8M $357.8M
YoY Change -29.85% -13.64% 21.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.072M $7.661M $4.306M
YoY Change 29.95% 26.8% -22.08%
Accrued Expenses $7.952M $8.922M $12.78M
YoY Change -18.05% -35.28% 65.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.746M $1.574M $1.542M
YoY Change 8.65% 9.08% 9.13%
Total Short-Term Liabilities $17.67M $18.29M $19.05M
YoY Change 1.68% -14.52% 28.67%
LONG-TERM LIABILITIES
Long-Term Debt $19.71M $21.88M $22.28M
YoY Change -8.14% -6.71% -6.47%
Other Long-Term Liabilities $34.02M $32.28M $31.09M
YoY Change -0.18% -41.46% -42.04%
Total Long-Term Liabilities $53.73M $54.16M $53.37M
YoY Change -3.26% -31.09% -31.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.67M $18.29M $19.05M
Total Long-Term Liabilities $53.73M $54.16M $53.37M
Total Liabilities $102.8M $105.1M $105.1M
YoY Change -2.13% -20.94% -16.09%
SHAREHOLDERS EQUITY
Retained Earnings -$1.035B -$899.8M -$875.0M
YoY Change 11.77% 13.96% 15.77%
Common Stock $516.0K $512.0K $495.0K
YoY Change 0.39% 6.67% 46.45%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.390M $630.0K $630.0K
YoY Change 59.02% 82.61% 82.61%
Treasury Stock Shares 1.281M shares 380.0K shares 380.0K shares
Shareholders Equity $140.8M $266.7M $252.8M
YoY Change
Total Liabilities & Shareholders Equity $243.6M $371.8M $357.8M
YoY Change -29.85% -13.64% 21.42%

Cashflow Statement

Concept 2014 Q1 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income -$30.84M -$24.87M -$29.54M
YoY Change 18.71% -26.51% 13.16%
Depreciation, Depletion And Amortization $644.0K $900.0K $1.100M
YoY Change -18.79% -18.18% -8.33%
Cash From Operating Activities -$30.32M -$20.50M -$25.00M
YoY Change 24.92% -8.89% 23.76%
INVESTING ACTIVITIES
Capital Expenditures $28.00K -$100.0K -$100.0K
YoY Change -96.66% -50.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $40.60M -$6.600M $11.70M
YoY Change 35.79% -136.07% -62.14%
Cash From Investing Activities $40.57M -$6.700M $11.60M
YoY Change 39.38% -137.02% -62.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $811.0K
YoY Change 29.97%
Debt Paid & Issued, Net $420.0K
YoY Change 8.53%
Cash From Financing Activities -$1.231M 36.80M 500.0K
YoY Change 21.76% -77.04% -225.0%
NET CHANGE
Cash From Operating Activities -$30.32M -20.50M -25.00M
Cash From Investing Activities $40.57M -6.700M 11.60M
Cash From Financing Activities -$1.231M 36.80M 500.0K
Net Change In Cash $9.018M 9.600M -12.90M
YoY Change 135.76% -93.84% -227.72%
FREE CASH FLOW
Cash From Operating Activities -$30.32M -$20.50M -$25.00M
Capital Expenditures $28.00K -$100.0K -$100.0K
Free Cash Flow -$30.35M -$20.40M -$24.90M
YoY Change 20.86% -8.52% 24.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9715000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7661000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
790000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1378000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7674000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8922000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83416000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
81945000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1166605000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1175108000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5707000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7421000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6495000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
552000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
266678000 USD
CY2013Q4 us-gaap Assets
Assets
274160000 USD
CY2012Q4 us-gaap Assets
Assets
371778000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
134554000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
230935000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37499000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30423000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186309000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47208000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7076000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-155886000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
139101000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
512000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
514000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110209000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-104147000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116199000 USD
CY2011 us-gaap Contracts Revenue
ContractsRevenue
1632000 USD
CY2012 us-gaap Contracts Revenue
ContractsRevenue
783000 USD
CY2013 us-gaap Contracts Revenue
ContractsRevenue
2109000 USD
CY2013Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0823
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-18745000 USD
CY2012Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-19085000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
128000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
195000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13910000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13405000 USD
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4760000 USD
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4906000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
348791000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
376611000 USD
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
83375000 USD
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
71839000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
238608000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
216579000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
444100000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
10429000 USD
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4712000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
32066000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
37453000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7703000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
12972000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-376611000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-348451000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
-18745000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
-18745000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-340000 USD
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
511000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
583000 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
490000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4887000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4190000 USD
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2863000 USD
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11700000 USD
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
9887000 USD
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
6766000 USD
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2210000 USD
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-35000000 USD
CY2010Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
48267000 USD
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
29920000 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27710000 USD
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
55033000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17043000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17121000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17350000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10365000 USD
CY2012 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2011 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
704000 USD
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2011 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
800000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3119000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
995000 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1028000 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-394000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-588000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
438000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
293000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
95000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
96000 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
414000 USD
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-865000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2601000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1713000 USD
CY2013 us-gaap Interest Expense
InterestExpense
1971000 USD
CY2011 us-gaap Interest Expense
InterestExpense
2528000 USD
CY2012 us-gaap Interest Expense
InterestExpense
2114000 USD
CY2012 us-gaap Interest Paid Net
InterestPaidNet
2028000 USD
CY2013 us-gaap Interest Paid Net
InterestPaidNet
1897000 USD
CY2011 us-gaap Interest Paid Net
InterestPaidNet
2447000 USD
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
255000 USD
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
157000 USD
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
213000 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2200000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1859000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2500000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
105100000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
103997000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371778000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
274160000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18285000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19294000 USD
CY2011 us-gaap Licenses Revenue
LicensesRevenue
217000 USD
CY2012 us-gaap Licenses Revenue
LicensesRevenue
306000 USD
CY2013 us-gaap Licenses Revenue
LicensesRevenue
113000 USD
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
21877000 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1710000 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1574000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1710000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
16293000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2015000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
21877000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
20167000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1389000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157084000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36381000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97807000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69955000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
99544000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91079000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94460000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87938000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-104126000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-116215000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-110211000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-25974000 USD
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-24873000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-31658000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-29539000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-29080000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-25931000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-29868000 USD
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-17414000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
104593000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
109504000 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
115944000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-108415000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-114095000 USD
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-24492000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28624000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25555000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4377000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
620000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
554000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1093000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1067000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1043000 USD
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
665300000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-102371000 USD
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-16976000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31216000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29060000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-29383000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25480000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4636000 USD
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6349000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144000 USD
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 USD
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21000 USD
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 USD
CY2013Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
53557000 USD
CY2012Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
53557000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32283000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32386000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
153000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
59000 USD
CY2011 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
108000 USD
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
873000 USD
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
285000 USD
CY2012Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000 USD
CY2012 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
233250000 USD
CY2013 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
111490000 USD
CY2011 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
108092000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1721000 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
492000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1206000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
38109000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
160781000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1084000 USD
CY2013 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-26000 USD
CY2012 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2011 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2011 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
176628000 USD
CY2012 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
135850000 USD
CY2013 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
212625000 USD
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
130000 USD
CY2011 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2625000 USD
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
85000 USD
CY2011Q2 us-gaap Proceeds From Sale Of Real Estate
ProceedsFromSaleOfRealEstate
2400000 USD
CY2011 us-gaap Profit Loss
ProfitLoss
-116215000 USD
CY2012 us-gaap Profit Loss
ProfitLoss
-110211000 USD
CY2013 us-gaap Profit Loss
ProfitLoss
-104126000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126050000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123307000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42634000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41362000 USD
CY2012 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2013 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2011 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3589000 USD
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1574000 USD
CY2012 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1443000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89682000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91828000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82574000 USD
CY2013Q4 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2012Q4 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-899832000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1003958000 USD
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
192785000 USD
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
91629000 USD
CY2012Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17500000 shares
CY2013 us-gaap Revenues
Revenues
2222000 USD
CY2011 us-gaap Revenues
Revenues
1849000 USD
CY2012 us-gaap Revenues
Revenues
1089000 USD
CY2013Q4 us-gaap Revenues
Revenues
1410000 USD
CY2013Q3 us-gaap Revenues
Revenues
238000 USD
CY2012Q3 us-gaap Revenues
Revenues
372000 USD
CY2013Q1 us-gaap Revenues
Revenues
360000 USD
CY2013Q2 us-gaap Revenues
Revenues
214000 USD
CY2012Q4 us-gaap Revenues
Revenues
218000 USD
CY2012Q2 us-gaap Revenues
Revenues
199000 USD
CY2012Q1 us-gaap Revenues
Revenues
300000 USD
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
7421000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
6495000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
5707000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
27548044 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
15537621 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
462000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
325000 USD
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
63000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.59
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.37
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.36
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1400000 USD
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1400000 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37055000 USD
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
160592000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
170163000 USD
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1084000 USD
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1054000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
247024000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
297568000 USD
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
814000 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
380000 shares
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
630000 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1503000 USD
CY2012 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-285000 USD
CY2013 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-873000 USD
CY2011 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-108000 USD
CY2011 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
16000 USD
CY2013 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-21000 USD
CY2012 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2000 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
28200000 USD
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
489707000 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
340761000 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
513117000 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
512428000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
513419000 shares
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
480324000 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
513083000 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
490049000 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
480634000 shares
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
513523000 shares
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
507619000 shares
CY2013Q4 lxrx Buildings Collateral
BuildingsCollateral
59100000 USD
CY2011 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
6766000 USD
CY2013 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
-2210000 USD
CY2012 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
9887000 USD
CY2001Q3 lxrx Coelacanth Goodwill
CoelacanthGoodwill
25800000 USD
CY2001Q3 lxrx Coelacanth Purchase Price
CoelacanthPurchasePrice
36000000 USD
CY2013Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
-18745000 USD
CY2012Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
-18745000 USD
CY2013Q4 lxrx Directors Annual Option Grant
DirectorsAnnualOptionGrant
20000 shares
CY2013Q4 lxrx Directors Annual Restricted Stock Award Value
DirectorsAnnualRestrictedStockAwardValue
20000 USD
CY2013Q4 lxrx Directors Intial Option Grant
DirectorsIntialOptionGrant
30000 shares
CY2012 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
1.00
CY2013 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
1.00
CY2011 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
1.00
CY2012 lxrx Entity Wide Revenue Deltagen Percentage
EntityWideRevenueDeltagenPercentage
0.25
CY2013 lxrx Entity Wide Revenue Mc Nair Medical Institute Percentage
EntityWideRevenueMcNairMedicalInstitutePercentage
0.57
CY2011 lxrx Entity Wide Revenue Taconic Farms Percentage
EntityWideRevenueTaconicFarmsPercentage
0.46
CY2013 lxrx Entity Wide Revenue Taconic Farms Percentage
EntityWideRevenueTaconicFarmsPercentage
0.33
CY2012 lxrx Entity Wide Revenue Taconic Farms Percentage
EntityWideRevenueTaconicFarmsPercentage
0.68
CY2011 lxrx Entity Wide Revenue Texas Am Institute For Genomic Medicine Percentage
EntityWideRevenueTexasAmInstituteForGenomicMedicinePercentage
0.20
CY2011 lxrx Entity Wide Revenue United States Army Medical Research Acquisition Activity Percentage
EntityWideRevenueUnitedStatesArmyMedicalResearchAcquisitionActivityPercentage
0.20
CY2007Q2 lxrx Holdings Contribution To Icon
HoldingsContributionToIcon
45000000 USD
CY2007Q3 lxrx Invus Purchase Shares
InvusPurchaseShares
50824986 shares
CY2013Q4 lxrx Land Collateral
LandCollateral
2700000 USD
CY2010Q3 lxrx Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
10000000 USD
CY2007Q2 lxrx Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
15000000 USD
CY2007Q2 lxrx Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
7650622 shares
CY2013Q4 lxrx Limit On Shares That May Be Issued Other Than Stock Options Or Sars Equity Incentive Plan
LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan
15000000 shares
CY2012Q4 lxrx Net Proceeds From Stock Offering
NetProceedsFromStockOffering
37100000 USD
CY2012Q4 lxrx Offering Price Per Share
OfferingPricePerShare
2.25
CY2013Q4 lxrx Options Outstanding Equity Incentive Plan
OptionsOutstandingEquityIncentivePlan
22342175 shares
CY2013Q4 lxrx Options Outstanding Non Employee Directors Equity Incentive Plan
OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
964000 shares
CY2012Q4 lxrx Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
2000000 USD
CY2013 lxrx Restricted Stock Purchase Price As Percent Of Value Of Common Stock
RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock
0.85
CY2013Q4 lxrx Restricted Stock Units Outstanding Equity Incentive Plan
RestrictedStockUnitsOutstandingEquityIncentivePlan
4241869 shares
CY2013 lxrx Revisionto Deferred Tax Assets
RevisiontoDeferredTaxAssets
13800000 USD
CY2012 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
94112 shares
CY2011 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
1.81
CY2013Q4 lxrx Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
1839850 shares
CY2013 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
1.98
CY2012 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
1.70
CY2013Q4 lxrx Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
174920 shares
CY2011Q4 lxrx Rights Offering Invus Ownership Percentage
RightsOfferingInvusOwnershipPercentage
0.50
CY2011Q4 lxrx Rights Offering Invus Shares
RightsOfferingInvusShares
115044247 shares
CY2004Q2 lxrx Woodlands Cash Paid
WoodlandsCashPaid
20800000 USD
CY2004Q2 lxrx Woodlands Mortgage
WoodlandsMortgage
34000000 USD
CY2014Q1 lxrx Workforce Reduction Percentageof Cash Expenditures High Endof Range
WorkforceReductionPercentageofCashExpendituresHighEndofRange
0.95
CY2013 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
80808 shares
CY2011 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
200277 shares
CY2011Q4 lxrx Rights Offering Net Proceeds
RightsOfferingNetProceeds
160600000 USD
CY2011Q4 lxrx Rights Offering Offering Expenses
RightsOfferingOfferingExpenses
400000 USD
CY2011Q4 lxrx Rights Offering Price Per Share
RightsOfferingPricePerShare
1.13
CY2011Q4 lxrx Rights Offering Shares
RightsOfferingShares
142492883 shares
CY2011Q4 lxrx Rights Offering Stock Price
RightsOfferingStockPrice
1.14
CY2013Q4 lxrx Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan
SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
740300 shares
CY2012 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
35000000 USD
CY2013 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2011 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2012 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
2822000 USD
CY2013 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
3045000 USD
CY2011 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
2458000 USD
CY2011 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
3249000 USD
CY2012 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
3673000 USD
CY2013 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
4376000 USD
CY2012Q4 lxrx Stock Issued During Period To Invus Shares
StockIssuedDuringPeriodToInvusShares
3000000 shares
CY2013 lxrx Stock Option Exercise Price As Percent Of Value Of Common Stock
StockOptionExercisePriceAsPercentOfValueOfCommonStock
1.00
CY2013Q4 lxrx Stock Options Exercised Equity Incentive Plan
StockOptionsExercisedEquityIncentivePlan
5659265 shares
CY2013Q4 lxrx Stock Options Exercised Non Employee Directors Equity Incentive Plan
StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
0 shares
CY2010Q3 lxrx Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
45600000 USD
CY2010Q3 lxrx Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
0.14
CY2012Q3 lxrx Symphony Base Payment In Shares
SymphonyBasePaymentInShares
13237519 shares
CY2012Q3 lxrx Symphony Base Payment Obligation
SymphonyBasePaymentObligation
35000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
0.18
CY2010Q3 lxrx Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
45000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Percentage
SymphonyContingentPaymentPercentage
0.50
CY2010Q3 lxrx Symphony Icon Goodwill
SymphonyIconGoodwill
18700000 USD
CY2010Q3 lxrx Symphony Payment In Stock Limitation
SymphonyPaymentInStockLimitation
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Payment
SymphonyRegulatoryApprovalPayment
15000000 USD
CY2010Q3 lxrx Symphony Regulatory Approval Percentage Limit
SymphonyRegulatoryApprovalPercentageLimit
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Reduction Percentage
SymphonyRegulatoryApprovalReductionPercentage
0.50
CY2013Q4 lxrx Tigm Maximum Exposure Through Reporting Date
TIGMMaximumExposureThroughReportingDate
1500000 USD
CY2012 lxrx Taconic Revenue
TaconicRevenue
700000 USD
CY2013 lxrx Taconic Revenue
TaconicRevenue
700000 USD
CY2011 lxrx Taconic Revenue
TaconicRevenue
800000 USD
CY2013Q4 lxrx Taconic Total Cash Received
TaconicTotalCashReceived
7500000 USD
CY2013Q4 lxrx Tigm Maximum Exposure
TigmMaximumExposure
14200000 USD
CY2013Q4 lxrx Tigm Per Job Payment Amount
TigmPerJobPaymentAmount
2415 USD
CY2013Q4 lxrx Total Shares That May Be Issued Equity Incentive Plan
TotalSharesThatMayBeIssuedEquityIncentivePlan
50000000 shares
CY2013Q4 lxrx Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan
TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
1500000 shares
CY2005Q3 lxrx Tx Enterprise Fund Award
TxEnterpriseFundAward
35000000 USD
CY2014Q1 lxrx Workforce Reduction Percentageof Cash Expenditures Low Endof Range
WorkforceReductionPercentageofCashExpendituresLowEndofRange
0.90
CY2014Q1 lxrx Workforce Reduction Termination Costs High Endof Range
WorkforceReductionTerminationCostsHighEndofRange
6000000 USD
CY2014Q1 lxrx Workforce Reduction Termination Costs Low Endof Range
WorkforceReductionTerminationCostsLowEndofRange
5000000 USD
CY2014Q1 lxrx Workforce Reduction Total Cost High Endof Range
WorkforceReductionTotalCostHighEndofRange
7000000 USD
CY2014Q1 lxrx Workforce Reduction Total Cost Low Endof Range
WorkforceReductionTotalCostLowEndofRange
6000000 USD
CY2005Q3 lxrx Tx Enterprise Fund Award To Texas Am University System
TxEnterpriseFundAwardToTexasAmUniversitySystem
15000000 USD
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
513790361 shares
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q2 dei Entity Public Float
EntityPublicFloat
493400000 USD
CY2013 dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No

Files In Submission

Name View Source Status
0001062822-14-000009-index-headers.html Edgar Link pending
0001062822-14-000009-index.html Edgar Link pending
0001062822-14-000009.txt Edgar Link pending
0001062822-14-000009-xbrl.zip Edgar Link pending
exh1013non-employeedirecto.htm Edgar Link pending
exh1023loanandsecurityagre.htm Edgar Link pending
exh231ernst_youngconsent10.htm Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10k12312012_charta01a01.jpg Edgar Link pending
form10k12312013.htm Edgar Link pending
lxrx-20131231.xml Edgar Link completed
lxrx-20131231.xsd Edgar Link pending
lxrx-20131231_cal.xml Edgar Link unprocessable
lxrx-20131231_def.xml Edgar Link unprocessable
lxrx-20131231_lab.xml Edgar Link unprocessable
lxrx-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending